Your browser doesn't support javascript.
loading
Abemaciclib pharmacology and interactions in the treatment of HR+/HER2- breast cancer: a critical review.
Martorana, Federica; Sanò, Maria Vita; Valerio, Maria Rosaria; Fogli, Stefano; Vigneri, Paolo; Danesi, Romano; Gebbia, Vittorio.
Afiliación
  • Martorana F; Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy.
  • Sanò MV; Medical Oncology Unit, Istituto Clinico Humanitas, Misterbianco, Catania, Italy.
  • Valerio MR; Medical Oncology Unit, Policlinico P. Giaccone, University of Palermo, Palermo, Italy.
  • Fogli S; Unit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
  • Vigneri P; Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy.
  • Danesi R; Medical Oncology Unit, Istituto Clinico Humanitas, Misterbianco, Catania, Italy.
  • Gebbia V; Unit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Ther Adv Drug Saf ; 15: 20420986231224214, 2024.
Article en En | MEDLINE | ID: mdl-38665218
ABSTRACT
Abemaciclib (ABE) in combination with endocrine therapy represents the mainstay treatment for either endocrine-resistant metastatic or high-risk early-stage HR+/HER2- breast cancer patients. Hence, an adequate knowledge of this agent pharmacodynamic, pharmacokinetic, and of its drug-drug interactions (DDIs) is crucial for an optimal patients management. Additionally, ABE interference with food and complementary/alternative medicines should be taken into account in the clinical practice. Several online tools allow to freely check DDIs and can be easily consulted before prescribing ABE. According to one of this instruments, ABE display the lowest number of interactions among the available cyclin-dependent kinase 4/6 inhibitors. Still, clinicians should be aware that online tools cannot replace the technical datasheet of the drug as well as a comprehensive clinical assessment for each patient. Here we critically review the main pharmacological features of ABE, then focusing on its potential interactions with drugs, food, and alternative medicine, in order to provide a guide for its optimal use in the treatment of HR+/HER2- breast cancer patients.
Pharmacological features and drug interactions of abemaciclib Why was the review done? Abemaciclib, paired with hormone therapy, is a key treatment for breast cancer patients whose cancer cells respond to hormones but not to a protein called HER2. Understanding how this medication functions in the body, how it interacts with other drugs, and how the body processes it is crucial for providing optimal care. What did the authors do? The authors looked for published evidence about the way abemaciclib works into the body and about how it interacts with other drugs (including alternative medicines) or food. Then they summarized these findings. What did the authors find? Abemaciclib absorption, distribution, metabolism and excretion is well known and it is here described. What people eat and any alternative medications they take can affect how abemaciclib works. Online tools are available for doctors to check potential interactions between abemaciclib and other drugs a patient might be using. It's advisable for doctors to consult abemaciclib data sheet and use online tools before prescribing the drug. Notably, compared to similar treatments, abemaciclib has fewer interactions with other drugs. What does the review mean? This review delves into how abemaciclib works in the body and explore its potential interactions with other drugs, food, and alternative medicines. This information will aid doctors in using abemaciclib effectively for treating breast cancer patients.
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Ther Adv Drug Saf Año: 2024 Tipo del documento: Article País de afiliación: Italia

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Ther Adv Drug Saf Año: 2024 Tipo del documento: Article País de afiliación: Italia